Interferon-β inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines

Journal of Neuro-Oncology

Volumn 30, Issue 3, 1996, Pages 213-223

  Garrison, Judith I ^a   Berens, Michael E ^b   Shapiro, Joan Rankin ^b   Treasurywala, Sherri ^a   Floyd Smith, Georgia ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

2 5A synthetase; Astrocyte; Cancer; Cell cycle; Cell death; Flow cytometry; Glioblastoma multiforme; Glioma; Interferon; Recurrent tumor

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; MESSENGER RNA; SYNTHETASE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GLIA CELL; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; METAPHASE; NORMAL HUMAN; NORTHERN BLOTTING;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTES; BLOTTING, NORTHERN; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; FLOW CYTOMETRY; G2 PHASE; GLIOMA; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MIDDLE AGED; S PHASE; TUMOR CELLS, CULTURED;

EID: 0029860955     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Janus TJ, Kyritsis AP, Forman AD, Levin VA: Biology and treatment of gliomas. Annals of Oncol 3: 423-433, 1992
2. Shapiro JR, Yung WKA, Shapiro WR: Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cane Res 41: 2349-2359, 1981
3. Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976-1981, 1983
4. Yung WK, Castellanos AM, Van Tassel P, Moser RP, Marcus SG: A pilot study of recombinant interf eron beta (IFN-beta ser) in patients with recurrent glioma. J Neuro-Oncol 9: 29-34, 1990
5. Atanasiu P, Chany C: Action d'un interferon provenant de cellules malignes sur l'infection expérimentale du Hamster nouveau-né par le virus du polyome. C R Acad Sci (Paris) 251: 1687-1689, 1960
6. Stuart II WE: The Interferon System. Springer-Verlag, New York, 1979, pp 292-303
7. Borden EC: Progress towards therapeutic application of interferons. Cancer 54: 2770-2776, 1984
8. Nelson BE, Borden EC: Interferons: biological and clinical effects. Semin Surg Oncol 5: 391-401, 1989
9. Dianzani F: Biological basis for therapy and for side effects. In: Baron S, Coppenhaver DH, Dianzani F, Fleischman Jr WR, Hughes Jr TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK (eds) Interferon: Principles and Medical Applications. The University of Texas Medical Branch at Galveston, Galveston, 1992, pp 409-416
10. Lengyel P: Tumor-suppressor gene: news about the interferon connection. Proc Natl Acad Sci USA 90: 5893-5895, 1993
11. Borden EC, Waalen J, Schreiber R, Williams B: Response and resistance to interferons and interacting cytokines. J Natl Cancer Inst 87: 257-264, 1995
12. Floyd-Smith G, Lengyel P: Mechanisms of interferon action: characteristics of RNase L, the (2′-5′) (A)-n-dependent endoribonuclease. In: Grunberg-Manago M, Safer B (eds) Interaction of Translational and Transcriptional Controls in the Regulation of Gene Expression. Elsevier Publ Co, North Holland, 1982, pp 417-433
13. 0/S-phase transition. Science 233: 356-359, 1986
14. 0/G, arrest. Nature 313: 597-600, 1985
15. Numa Y, Kawamoto K, Sakai M, Matsumura H: Flow cytometric analysis of antineoplastic effects of interferon-α, -β and -γ labelled with fluorescein isothiocyanate on cultured brain tumors. J Neuro-Oncol 11: 225-234, 1991
16. Kimchi A: Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 50: 1-9, 1992
17. Pape KA, Floyd-Smith G: Effects of interferon-β on Daudi cells and on small cell lung carcinoma cells which over-express the c-myc oncogene. Anticancer Res 9: 1737-1742, 1989
18. Pantazis P, Pelicci PG, Dalla-Favera R, Antoniades HN: Synthesis and secretion of proteins resembling platelet-derived growth factor by human gliobastoma and fibrosarcoma cells in culture. Proc Natl Acad Sci USA 82: 2404-2408, 1985
19. Shapiro JR, Mehta BM, Ebrahim SAD, Scheck AC, Moots RL, Fiola MR: Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas. In: Sudilovsky O, Pilot HC, Liotta LA (eds) Boundaries between Promotion and Progression during Carcinogenesis. Plenum Publ Corp, New York, 1991, pp 243-262
20. Berens ME, Rief MD, Loo MA, Giese A: The role of extra-cellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay. Clin Exp Metastasis 12: 405-415, 1994
21. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1985
22. Burghardt RC, Barhoumi R, Doolittle DJ, Phillips TD: Application of cellular fluorescence imaging for in vitro toxicology testing. In: Hayes AW (ed.) Principles and Methods of Toxicology, 3rd ed. Raven Press, New York, 1994, pp 1231-1258
23. Coons SW, Johnson PC: Regional heterogeneity in the DNA content of human gliomas. Cancer 72: 3052-3060, 1993
24. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
25. Puissant C, Houdebine LM: An improvement of the single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. BioTech 8: 148-149, 1990
26. Henderson GS, Conary JT, Davidson JM, Stewart SJ, House FS, McCurley TL: A reliable method for northern blot analysis using synthetic oligonucleotide probes. BioTech 10: 190-197, 1991
27. Shih N-Y, Floyd-Smith G: Invariant chain (CD74) gene regulation: Enhanced expression associated with activation of protein kinase Cδ in a murine B lymphoma cell line. Mol Immunol 32: 643-650, 1995
28. Benech P, Mory Y, Revel M, Chebath J: Structure of two forms of the interferon-induced (2′-5′) oligo A synthetase of human cells based on cDNAs and gene sequences. EMBO J 4: 2249-2256, 1985
29. Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 263: 15335-15341, 1988
30. Deng GR, Wu R: Terminal transferase: use in the tailing of DNA and for in vitro mutagenesis. Meth Enzymol 100: 96-116, 1983
31. Nikkhah G, Tonn JC, Hoffmann O, Kraemer H-P, Darling JL, Schonmayr R, Schschenmayr W: The MTT assay for chernosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables. J Neuro-Oncol 13: 1-11, 1992
32. Bradley NJ, Darling JL, Oktar N, Bloom HJG, Savis AJS: The failure of human leukocyte interferon to influence the growth of human glioma cell populations: In vitro and in vivo studies. Br J Cancer 48: 819-825, 1983
33. Cook AW, Carter WA, Nidzgorsiki F, Akhtar L: Human brain tumor-derived cell lines: Growth rate reduced by human fibroblast interferon. Science 219: 881-883, 1983
34. Rosenblum MG, Yung WKA, Kelleher PJ, Ruzicka F, Steck PA, Borden EC: Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: Correlation of receptor binding, 2′-5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10: 141-151, 1990
35. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 56: 727-777, 1987
36. Munoz-Fernandez MA, Armas-Portela R, Diaz-Nido J, Alonso JL, Fresno M, Avila J: Differential effects of tumor necrosis factor on the growth and differentiation of neuroblastoma and glioma cells. Exp Cell Res 194: 161-164, 1991
37. Tejada-Berges T, Yong VW: The astrocyte mitogen, tumor necrosis factor-alpha, inhibits the proliferative effects of more potent adult human astrocyte mitogens, gamma-interferon and activated T-lymphocyte supernatant. Brain Res 653: 297-304, 1994
38. Alfinito F, Lamberti A, Capobianchi MR, Nigro M, De Rosa G, Tassone P, Turco MC, Dianzani F, Venuta S: T cell growth-promoting activity of interferon-gamma. Mitogenic effect of the recombinant cytokine on cells from a human T-chronic lymphocytic leukemia. Leukemia 8: 1294-1300, 1994
39. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 24: 2377-2382, 1994
40. Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in responses to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994
41. Uzé G, Lutfalla G, Gresser I: Genetic transfer of a functional human interferon a receptor into mouse cells: cloning and expression of its cDNA. Cell 60: 225-234, 1990
42. Novick D, Cohen B, Rubinstein M: The human interferon α/β receptor: characterization and molecular cloning. Cell 77: 391-400, 1994
43. Yates JA, Stephens RE, Elder PJ, Markowitz PL, Rice JM: Effects of interferon and gangliosides on growth of cultured human glioma and fetal brain cells. Cancer Res 45: 1033-1039, 1985
44. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148: 1274-1279, 1992
45. Yoshida J, Mizuno M, Yagi K: Cytotoxicity of human beta-interferon produced in human glioma cells permanently transfected with its gene by means of liposomes. Biochem Int 28: 1055-1061, 1992
46. 1 phase progression: cycling on cue. Cell 79: 551-555, 1994
47. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994
48. King RW, Jackson PK, Kirschner M: Mitosis in transition. Cell 79: 563-571, 1994
49. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259: 971-974, 1993